Prosecution Insights
Last updated: April 19, 2026
Application No. 18/655,886

METHOD FOR IMPROVING MEAT QUALITY

Non-Final OA §102§103§DP
Filed
May 06, 2024
Examiner
LOVE, TREVOR M
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Can Technologies Inc.
OA Round
1 (Non-Final)
43%
Grant Probability
Moderate
1-2
OA Rounds
3y 6m
To Grant
68%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allow Rate
301 granted / 703 resolved
-17.2% vs TC avg
Strong +25% interview lift
Without
With
+24.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
739
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
50.9%
+10.9% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
14.6%
-25.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 703 resolved cases

Office Action

§102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-23 are pending and are currently under consideration. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-23 (all claims currently under consideration) is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Van den Bosch et al (WO 2016/090366) (IDS Reference). Van den Bosch teaches an animal feed for monogastric animals, and specifically names sows (see entire document, for instance, [0008]). Van den Bosch teaches a standard diet comprising the composition of Table 1A (see entire document, for instance, [00045] and pages 15 and 16). The composition comprises 0.1% calcium nitrate, and specifically, Bolifor (see entire document, for instance, Table 1A), note that the instant specification indicates that Bolifor contains about 63% nitrate (see instant [00024] as well as Van den Bosch [00045]), which means the composition of Van den Bosch comprises 0.063% nitrate. Van den Bosch teaches that the method of Van den Bosch results in vasodilation benefits, but also has further additional benefits, such as color and meat quality (see entire document, for instance, [00034]). The pigs are taught as being at various stages, including piglets, barrows, gilts, boars, and sows (see entire document, for instance, [00037]). It is noted that the pigs can be fed the diet of Van den Bosch at least through farrowing (see entire document, for instance, claim 15). Applicant is reminded that the intended use of a product claim carries no patentable weight unless it imparts a structural limitation. See MPEP 2111.02. Therefore, since the intended use of the composition as improving the redness of meat is merely identifying that the composition can be used in such a way as to have said effect, and not imparting a structural limitation, it is the Examiner's position that the composition is capable of performing the intended use. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-23 (all claims currently under consideration) is/are rejected under 35 U.S.C. 103 as being unpatentable over Van den Bosch et al (WO 2016/090366) (IDS Reference). Van den Bosch teaches an animal feed for monogastric animals, and specifically names sows (see entire document, for instance, [0008]). Van den Bosch teaches a standard diet comprising the composition of Table 1A (see entire document, for instance, [00045] and pages 15 and 16). The composition comprises 0.1% calcium nitrate, and specifically, Bolifor (see entire document, for instance, Table 1A), note that the instant specification indicates that Bolifor contains about 63% nitrate (see instant [00024] as well as Van den Bosch [00045]), which means the composition of Van den Bosch comprises 0.063% nitrate. Van den Bosch teaches that the method of Van den Bosch results in vasodilation benefits, but also has further additional benefits, such as color and meat quality (see entire document, for instance, [00034]). The pigs are taught as being at various stages, including piglets, barrows, gilts, boars, and sows (see entire document, for instance, [00037]). It is noted that the pigs can be fed the diet of Van den Bosch at least through farrowing (see entire document, for instance, claim 15). Van der Bosch, while teaching all of the instantly claimed components and the instantly claimed method, does not expressly articulate all of the claimed properties and comparisons of the composition to animals that have not undergone the instantly claimed method. It would have been obvious to one of ordinary skill in the art, before the effective filing date of the instantly claimed invention to follow the method as taught by Van der Bosch, and arrive at the instantly claimed invention. One would have been motivated to do so since Van der Bosch teaches the instantly claimed method steps utilizing the instantly claimed composition. It is noted that anticipation is the epitome of obviousness. Applicant is reminded that the intended use of a product claim carries no patentable weight unless it imparts a structural limitation. See MPEP 2111.02. Therefore, since the intended use of the composition as improving the redness of meat is merely identifying that the composition can be used in such a way as to have said effect, and not imparting a structural limitation, it is the Examiner's position that the composition is capable of performing the intended use. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 11,547,126. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are directed to a method of improving meat quality in swine comprising feeding the pigs a diet comprising 0.01-1% nitrate, wherein the feeding is during one of the weaning phase, the growth phase, the finishing phase, or combinations of the phases, and wherein the nitrate is at least 0/06% of the daily diet, and wherein the nitrate is calcium nitrate (see claims 1-11). Claims 1-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 12,004,538. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims are directed to a swine feed composition that is effective to increase the red color of the meat obtained when fed during the weaning phase, the growth phase, the finishing phase, or combinations of the phases. The diet comprising 0.02-0.07 nitrate, wherein the nitrate is selected from the group including calcium nitrate (see claims 1-8). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR M LOVE whose telephone number is (571)270-5259. The examiner can normally be reached M-F typically 6:30-3. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached on 5712726175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TREVOR LOVE/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

May 06, 2024
Application Filed
May 28, 2024
Response after Non-Final Action
Jan 29, 2026
Non-Final Rejection — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599643
USE OF GREEN COFFEE BASED COMPOSITIONS FOR IMPROVING INSULIN PROFILE
2y 5m to grant Granted Apr 14, 2026
Patent 12599695
ABSORBABLE SUTURE CONTAINING POLYDEOXYRIBONUCLEOTIDE
2y 5m to grant Granted Apr 14, 2026
Patent 12594317
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING NOVEL CORONAVIRUS PNEUMONIA, PREPARATION METHOD, DETECTION METHOD, AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12575571
1-AMINO-1-CYCLOPROPANECARBOXYLIC ACID AND METHYL JASMONATE MIXTURES AND USES THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12575563
SURFACTANTS FOR AGRICULTURAL PRODUCTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
43%
Grant Probability
68%
With Interview (+24.9%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 703 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month